Regenerative and advanced therapies include a wide range of products and procedures with very different levels of evidence and regulatory status. At My Concierge MD, David Nazarian, MD evaluates these options individually rather than presenting them as a single proven category of treatment.
Some interventions have established uses in defined medical settings. (For additional treatment information, see our PRP treatment website.) Others remain investigational, off-label, or supported by limited human evidence. A responsible consultation should identify the exact therapy, intended use, potential benefits, known risks, alternatives, and what is still uncertain.
Therapies Should Be Evaluated Separately
- Platelet-rich plasma and platelet-rich fibrin: evidence varies by indication, preparation, and patient selection.
- Growth-factor approaches: composition, evidence, and regulatory status depend on the specific product and use.
- Exosome products: proposed therapeutic uses remain investigational; broad anti-aging or tissue-regeneration claims should not be treated as established.
- Cell-based therapies: approved uses for specific diseases do not establish effectiveness for unrelated orthopedic, wellness, or anti-aging applications.
- Therapeutic plasma exchange: an established medical procedure for certain conditions, but longevity or preventive applications require separate evidence and individualized risk-benefit discussion.
- Peptide therapies: evidence and regulatory status vary substantially by molecule and indication.
Start With the Diagnosis
Joint pain, fatigue, hair loss, skin concerns, metabolic disease, and age-related symptoms can have many causes. The first step is not choosing a regenerative therapy. It is identifying the underlying problem and comparing any proposed intervention with established alternatives.
Evidence, Regulation, and Informed Consent
A biological mechanism, laboratory experiment, animal study, or early clinical report does not by itself establish a safe and effective treatment in people. Patients should understand whether a proposed therapy is FDA approved for the intended use, used off-label, compounded, investigational, or available only in a clinical-trial context.
How Regenerative Therapies Differ From Longevity Care
Regenerative medicine is an umbrella term for approaches intended to support tissue repair or function, but individual procedures vary substantially in their evidence, safety, and regulatory status. This page focuses on procedure-specific evaluation, including stem-cell injection evidence and FDA considerations. For long-term cardiovascular, metabolic, and preventive health planning, see our separate Longevity Medicine program. Not every regenerative intervention is approved or appropriate for routine clinical care.
Emerging therapies should not replace the foundations of longevity medicine: cardiovascular and metabolic risk reduction, exercise, nutrition, sleep, appropriate screening, and treatment of diagnosed conditions. They should be considered only when the evidence, regulatory status, alternatives, and patient-specific risks are understood.
Related Advanced-Therapy Pages
- Therapeutic Plasma Exchange
- Exosome Therapy
- Regenerative Hair Treatments
- Growth Factor Injections
- Physician-Guided Peptide Therapy
Frequently Asked Questions
Is regenerative medicine one type of treatment?
No. It is a broad term covering many different products and procedures. Evidence for one treatment or condition cannot be generalized to another.
Does physician supervision make an investigational therapy proven?
No. Physician oversight is important for assessment, informed consent, and monitoring, but it does not change the evidence or regulatory status of a therapy.
How should I evaluate an emerging therapy?
Ask about the exact product, intended use, human evidence, regulatory status, known risks, alternatives, and whether treatment could delay established care.
Written by David Nazarian, MD
Board Certified in Internal Medicine
Founder, My Concierge MD
Medically reviewed by David Nazarian, MD on